Scanning the HIV genome for CD4+ T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule

Journal of Immunology

Volumn 176, Issue 9, 2006, Pages 5401-5408

  Cohen, William M ^a   Pouvelle Moratille, Sandra ^a   Wang, Xiao Fei ^a   Farci, Sandrine ^a   Munier, Gaetan ^a   Charron, Dominique ^b   Ménez, André ^a   Busson, Marc ^b   Maillère, Bernard ^a  

^a CEA SACLAY   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE;

ARTICLE; BINDING SITE; ENZYME LINKED IMMUNOSPOT ASSAY; GENOTYPE; HLA SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS GENOME; VIRUS INFECTION;

EID: 33645982242     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.9.5401     Document Type: Article

References (44)

1. Castelli, F. A., C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J. G. Guillet, A. Menez, B. Georges, and B. Maillere. 2002. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 169: 6928-6934.
2. Charron, D., R. Fauchet, E. Albert, J. Bodmer, A. Cambon-Thomsen, L. Degos, J. Hors, A. Piazza, and I. Schreuder. 1997. Genetic diversity of HLA, functional and medical Implication. In XIItH International Histocompatibility Workshop and conference. D. Charron, ed. EDK, Paris, France.
3. + cytolytic T lymphocytes. Cancer Res. 60: 6272-6275.
4. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 98: 3964-3969.
5. + T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174: 1633-1640.
6. Schuler-Thurner, B., E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195: 1279-1288.
7. Schultz, E. S., B. Schuler-Thurner, V. Stroobant, L. Jenne, T. G. Berger, K. Thielemanns, P. van der Bruggen, and G. Schuler. 2004. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J. Immunol. 172: 1304-1310.
8. Zhang, Y., N. Renkvist, Z. Sun, B. Schuler-Thurner, N. Glaichenhaus, G. Schuler, T. Boon, P. van der Bruggen, and D. Colau. 2005. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 35: 1066-1075.
9. Celis, E., and R. W. Karr. 1989. Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule. J. Virol. 63: 747-752.
10. Koelle, D. M., S. N. Reymond, H. Chen, W. W. Kwok, C. McClurkan. T. Gyaltsong, E. W. Petersdorf, W. Rotkis, A. R. Talley, and D. A. Harrison. 2000. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J. Virol. 74: 10930-10938.
11. de Graaff, P. M., J. Heidema, M. C. Poelen, M. E. van Dijk, M. V. Lukens, S. P. van Gestel, J. Reinders, E. Rozemuller, M. Tilanus, P. Hoogerhout, et al. 2004. HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology 326: 220-230.
12. + T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr. Opin. Immunol. 13: 483-488.
13. + T cell proliferation. Proc. Natl. Acad. Sci. USA 98: 13878-13883.
14. + T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J. Virol. 78: 12638-12646.
15. + T cells. J. Exp. Med. 200: 701-712.
16. + T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77: 10900-10909.
17. + T cells endowed with proliferative capacity. J. Exp. Med. 198: 1909-1922.
18. + T cell maturation and function. J. Immunol. 172: 3337-3347.
19. + T cell responses associated with control of viremia. Science 278: 1447-1450.
20. + T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J. Immunol. 173: 2184-2189.
21. Wilson, C. C., B. Palmer, S. Southwood, J. Sidney, Y. Higashimoto, E. Appella, R. Chesnut, A. Sette, and B. D. Livingston. 2001. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J. Virol. 75: 4195-4207.
22. Malhotra, U., S. Holte, S. Dutta, M. M. Berrey, E. Delpit, D. M. Koelle, A. Sette, L. Corey, and M. J. McElrath. 2001. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest. 107: 505-517.
23. + T-cell clones from an HIV-1-seronegative donor following in vitro immunization. J. Virol. 76: 6987-6999.
24. Kaufmann, D. E., P. M. Bailey, J. Sidney, B. Wagner, P. J. Norris, M. N. Johnston, L. A. Cosimi, M. M. Addo, M. Lichterfeld, M. Altfeld, et al. 2004. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78: 4463-4477.
25. + T-cell clones generated from HIV-1-uninfected donors. Vaccine 12: 117-128.
26. Malhotra, U., S. Holte, T. Zhu, E. Delpit, C. Huntsberry, A. Sette, R. Shankarappa, J. Maenza, L. Corey, and M. J. McElrath. 2003. Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J. Virol. 77: 2663-2674.
27. + T cells can discriminate the molecular and structural context of T epitopes of HIV gp120 and HIV p66. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9: 227-237.
28. + T cells by at least four unrelated HLA-DR molecules. J. Immunol. 162: 152-160.
29. + T cells. Clin. Exp. Immunol. 129: 429-437.
30. Texier, C., S. Pouvelle, M. Busson, M. Herve, D. Charron, A. Menez, and B. Maillere. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164: 3177-3184.
31. + T lymphocytes. J. Exp. Med. 189: 767-778.
32. + T cells. Proc. Natl. Acad. Sci. USA 97: 400-405.
33. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160: 3363-3373.
34. Sturniolo, T., E. Bono, J. Ding, L. Raddrizzani, O. Tuereci, U. Sahin, M. Braxenthaler, F. Gallazzi, M. P. Protti, F. Sinigaglia, and J. Hammer. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices [see comments]. Nat Biotechnol. 17: 555-561.
35. Raddrizzani, L., T. Sturniolo, J. Guenot, E. Bono, F. Gallazzi, Z. A. Nagy, F. Sinigaglia, and J. Hammer. 1997. Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J. Immunol. 159:703-711.
36. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
37. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H. G. Rammensee. 1994. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39: 230-242.
38. Tangri, S., B. R. Mothe, J. Eisenbraun, J. Sidney, S. Southwood, K. Briggs, J. Zinckgraf, P. Bilsel, M. Newman, R. Chesnut, et al. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174: 3187-3196.
39. Jenkins, D. E., L. L. Yasukawa, R. Bergen, C. Benike, E. G. Engleman, and A. M. Arvin. 1999, Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. J. Immunol. 162: 560-567.
40. Geretti, A. M., C. A. Van Baalen, J. C. Borleffs, C. A. Van Els, and A. D. Osterhaus. 1994. Kinetics and specificities of the T helper-cell response to gp120 in the asymptomatic stage of HIV-1 infection. Scand. J. Immunol. 39: 355-362.
41. Alter, G., G. Hatzakis, C. M. Tsoukas, K. Pelley, D. Rouleau, R. LeBlanc, J. G. Baril, H. Dion, E. Lefebvre, R. Thomas, et al. 2003. Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J. Immunol. 171: 477-488.
42. Peretz, Y., G. Alter, M. P. Boisvert, G. Hatzakis, C. M. Tsoukas, and N. F. Bernard. 2005. Human immunodeficiency virus (HIV)-specific γ interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. J. Virol. 79: 4908-4917.
43. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5: 518-525.
44. Gahery-Segard, H., G. Pialoux, B. Charmeteau, S. Sermet, H. Poncelet, M. Raux, A. Tartar, J. P. Levy, H. Gras-Masse, and J. G. Guillet. 2000. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol. 74: 1694-1703.